These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 16989274)
41. Transcutaneous vaccines--current and emerging strategies. Hirobe S; Okada N; Nakagawa S Expert Opin Drug Deliv; 2013 Apr; 10(4):485-98. PubMed ID: 23316778 [TBL] [Abstract][Full Text] [Related]
42. Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination. Wang T; Wang N Curr Pharm Des; 2015; 21(36):5245-55. PubMed ID: 26412356 [TBL] [Abstract][Full Text] [Related]
43. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120 [TBL] [Abstract][Full Text] [Related]
49. Transcutaneous immunization with influenza vaccines. Skountzou I; Kang SM Curr Top Microbiol Immunol; 2009; 333():347-68. PubMed ID: 19768414 [TBL] [Abstract][Full Text] [Related]
50. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Zaharoff DA; Rogers CJ; Hance KW; Schlom J; Greiner JW Vaccine; 2007 Mar; 25(11):2085-94. PubMed ID: 17258843 [TBL] [Abstract][Full Text] [Related]
51. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Durando P; Iudici R; Alicino C; Alberti M; de Florentis D; Ansaldi F; Icardi G Hum Vaccin; 2011; 7 Suppl():29-40. PubMed ID: 21245655 [TBL] [Abstract][Full Text] [Related]
52. Initiation of adaptive immune responses by transcutaneous immunization. Warger T; Schild H; Rechtsteiner G Immunol Lett; 2007 Mar; 109(1):13-20. PubMed ID: 17320194 [TBL] [Abstract][Full Text] [Related]
54. An update on the use of laser technology in skin vaccination. Chen X; Wang J; Shah D; Wu MX Expert Rev Vaccines; 2013 Nov; 12(11):1313-23. PubMed ID: 24127871 [TBL] [Abstract][Full Text] [Related]
55. Adjuvantation of epidermal powder immunization. Chen D; Erickson CA; Endres RL; Periwal SB; Chu Q; Shu C; Maa YF; Payne LG Vaccine; 2001 Apr; 19(20-22):2908-17. PubMed ID: 11282202 [TBL] [Abstract][Full Text] [Related]
57. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573 [TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318 [TBL] [Abstract][Full Text] [Related]
59. [From basic principles to clinical applications on transcutaneous vaccine]. Okada N Yakugaku Zasshi; 2013; 133(12):1363-72. PubMed ID: 24292185 [TBL] [Abstract][Full Text] [Related]
60. Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines. An M; Liu H Small; 2017 Jul; 13(26):. PubMed ID: 28544329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]